Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis

详细信息    查看全文

• 作者：Xiaogang Wang ; Xiaoming Li ; Feng Xu ; Youqian Zhang ; Hongwei Liu…
• 关键词：TERT promoter mutation ; Gliomas ; Survival
• 刊名：Molecular Neurobiology
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：53
• 期：4
• 页码：2726-2732
• 全文大小：513 KB
• 参考文献：1.Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–403CrossRef PubMed
  2.Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310(17):1842–1850CrossRef PubMed
  3.Jansen M, Yip S, Louis DN (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9(7):717–726CrossRef PubMed PubMedCentral
  4.Turkalp Z, Karamchandani J, Das S (2014) IDH mutation in glioma: new insights and promises for the future. JAMA Neurol 71(10):1319–1325CrossRef PubMed
  5.Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ (2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 12(1):83–91CrossRef PubMed
  6.Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A, Kumar R (2015) TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 17(1):45–52
  7.Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110(15):6021–6026CrossRef PubMed PubMedCentral
  8.Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML et al (2014) Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46(7):731–735CrossRef PubMed PubMedCentral
  9.Fredriksson NJ, Ny L, Nilsson JA, Larsson E (2014) Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet 46:1258–63CrossRef PubMed
  10.Heidenreich B, Rachakonda PS, Hemminki K, Kumar R (2014) TERT promoter mutations in cancer development. Curr Opin Genet Dev 24:30–37CrossRef PubMed
  11.Chen C, Han S, Meng L, Li Z, Zhang X, Wu A (2014) TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. PLoS One 9(6):e100297CrossRef PubMed PubMedCentral
  12.Labussiere M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Paterra R et al (2014) TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 111(10):2024–2032CrossRef PubMed PubMedCentral
  13.Dorris K, Sobo M, Onar-Thomas A, Panditharatna E, Stevenson CB, Gardner SL, Dewire MD, Pierson CR et al (2014) Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas. J Neurooncol 117(1):67–76CrossRef PubMed PubMedCentral
  14.Sun H, Yin L, Li S, Han S, Song G, Liu N, Yan C (2013) Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis. J Neurooncol 113(2):277–284CrossRef PubMed
  15.Lotsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J et al (2013) Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol 15(4):423–432CrossRef PubMed PubMedCentral
  16.Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5(6):1515–1525CrossRef PubMed PubMedCentral
  17.Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute Web site
  18.Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10(1):101–129CrossRef
  19.Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560CrossRef PubMed PubMedCentral
  20.DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRef PubMed
  21.Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed
  22.Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634CrossRef PubMed PubMedCentral
  23.Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRef PubMed
  24.Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2007) Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 26(25):4544–4562CrossRef PubMed
  25.Labussiere M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O et al (2014) Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83(13):1200–1206CrossRef PubMed
  26.Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126(6):931–937CrossRef PubMed
  27.Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM et al (2013) TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 126(6):917–929CrossRef PubMed PubMedCentral
  28.Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372(26):2499–2508CrossRef PubMed PubMedCentral
  29.Heidenreich B, Rachakonda PS, Hosen I, Volz F, Hemminki K, Weyerbrock A, Kumar R (2015) TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget 6(12):10617–10633CrossRef PubMed PubMedCentral
  30.Mosrati MA, Malmstrom A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, Hallbeck AL, Bratthall C et al (2015) TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 6(18):16663–16673CrossRef PubMed PubMedCentral
  31.Spiegl-Kreinecker S, Lotsch D, Ghanim B, Pirker C, Mohr T, Laaber M, Weis S, Olschowski A, Webersinke G, Pichler J, Berger W (2015) Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol
  32.Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129(5):679–693CrossRef PubMed
  33.Huncharek M, Kupelnick B (2000) Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 12(2):107–112PubMed
  34.Cheng HB, Yue W, Xie C, Zhang RY, Hu SS, Wang Z (2013) IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis. Tumour Biol 34(6):3555–3559CrossRef PubMed
  35.Xiao WZ, Han DH, Wang F, Wang YQ, Zhu YH, Wu YF, Liu NT, Sun JY (2014) Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis. Tumour Biol 35(7):6687–6693CrossRef PubMed
  36.Long S, Argyle DJ, Nixon C, Nicholson I, Botteron C, Olby N, Platt S, Smith K et al (2006) Telomerase reverse transcriptase (TERT) expression and proliferation in canine brain tumours. Neuropathol Appl Neurobiol 32(6):662–673CrossRef PubMed
  37.Bodvarsdottir SK, Steinarsdottir M, Hilmarsdottir H, Jonasson JG, Eyfjord JE (2007) MYC amplification and TERT expression in breast tumor progression. Cancer Genet Cytogenet 176(2):93–99CrossRef PubMed
  38.Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P, Melo M, Catarino T et al (2014) Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch 465(2):119–133CrossRef PubMed
  39.Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961CrossRef PubMed
  40.Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959CrossRef PubMed PubMedCentral
  
• 作者单位：Xiaogang Wang (1)
  Xiaoming Li (1)
  Feng Xu (1)
  Youqian Zhang (1)
  Hongwei Liu (2)
  Yingqun Tao (1)
  
  1. Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang, 110840, China
  2. Department of Neuroscience, Xiangya Hospital, Central South University, Changsha, 410008, China
  
• 刊物主题：Neurosciences; Neurobiology; Cell Biology; Neurology;
• 出版者：Springer US
• ISSN：1559-1182

文摘

Previous studies have found that telomerase reverse transcriptase (TERT) has vital roles in the development of malignant diseases including glioma. The occurrence of TERT promoter mutations in gliomas is frequent. So far, several studies on the association between TERT promoter mutations and prognosis of gliomas had been published, but the conclusion was still not uncertain. The aim of the present meta-analysis was to assess the association between TERT promoter mutations and survival of glioma patients by pooling data from published studies. PubMed, Embase, and Web of Science were searched for articles on the association between TERT promoter mutations and survival of glioma patients until June 30, 2015. Hazard ratios (HR) and the 95 % confidence intervals (CIs) were utilized to analyze the prognosis of glioma patients with TERT promoter mutations. Heterogeneity of included studies was assessed using Cochrane’s Q test and I 2 method. Eleven studies with a total of 3,444 glioma patients were finally included into the meta-analysis. Nine studies reported the HRs adjusting for other confounding factors. Meta-analysis of total 11 studies suggested that TERT promoter mutations were significantly associated with worse prognosis of patients with gliomas (HR = 2.07, 95 % CI = 1.58–2.71, P < 0.00001). Meta-analysis of nine studies with adjusted outcomes suggested that TERT promoter mutations were independently associated with worse prognosis of patients with gliomas (HR = 2.28, 95 % CI = 1.72–3.01, P < 0.00001). In conclusion, TERT promoter mutation is a promising biomarker for predicting worse prognosis for patients with gliomas. More prospective well-designed cohort studies are needed to further validate its prognostic role in gliomas.